ABSTRACT
ABSTRACT Introduction: Vaccines are well-established public health interventions with major impacton the prevalence of infectious diseases, but outbreaks are occurring frequently due to pri-mary and secondary failures, despite high coverage. Surveillance of efficacy and duration ofinduced immunity is a difficult task as it requires invasive blood sampling in children andteenagers. Saliva can be an acceptable alternative source of IgG to assess vaccine efficacyand toxoplasmosis incidence. We investigated IgG response for measles, mumps, rubella,and T. gondii in saliva samples of vaccinated young people. Methods: Saliva was collected from 249 public schools students from São Paulo, Brazil, aged7 to 13 years old, during an interactive exhibition on hygiene. We used S. aureus proteinA solid phase capture assay for IgG reactive to biotinylated purified proteins. Paired salivaand serum (47) were tested from young adults with serum evidence of T. gondii infectionand from negative children less than 12 month old for standardization. Reproducibility wasgreater than 98% and sensitivity and specificity of the saliva assays were greater than 95%,as well as the concordance of paired saliva and serum samples. Results: Saliva from high school students showed a prevalence of 8.5% (95% CI: 5.0-11.9%)for anti T. gondii IgG; 96.8% (94.6-99%) of anti-measles IgG; 59.1% (53-65%) of anti-rubella IgG,and 57.5% (51.3-63.6%) of anti-mumps IgG. Discussion: The prevalence of antibodies against mumps and rubella after 6-8 years of vaccination was lower than against measles among students. The findings of this study demonstrate the feasibility of saliva sampling for follow-up of vaccine immune status in teenagers. This useful approach allows for IgG detection for vaccine control or epidemio- logical studies.
Subject(s)
Humans , Male , Female , Child , Adolescent , Saliva/immunology , Students/statistics & numerical data , Immunoglobulin G/analysis , Antibodies, Protozoan/analysis , Measles-Mumps-Rubella Vaccine/immunology , Antibodies, Viral/analysis , Reference Values , Rubella/immunology , Rubella/prevention & control , Brazil , Immunoglobulin G/immunology , Enzyme-Linked Immunosorbent Assay , Toxoplasmosis/immunology , Toxoplasmosis/prevention & control , ROC Curve , Immunoenzyme Techniques , Measles/immunology , Measles/prevention & control , Mumps/immunology , Mumps/prevention & controlABSTRACT
ABSTRACT Introduction: Immune response to vaccination in infants born prematurely may be lower than in infants born at full-term. Some clinical factors might be associated with humoral immune response. Objectives: The objectives of this study were to compare the immune response to measles and varicella vaccination in infants born prematurely with those born at full-term and to analyze factors associated with measles and varicella antibody levels. Methods: Prospective study including two groups of infants aged 12 months. One group of infants born prematurely with birth-weight <1500 g and who were in follow-up at the outpatient clinic for preterm infants at the institution and other group of infants born at full-term. Infants with malformations, primary immunodeficiency diseases, born to HIV-positive mothers or who had received plasma or immunoglobulin transfusions five months before or three weeks after vaccination were excluded. Plasma antibodies were measured by ELISA and factors associated with antibody levels were assessed by linear regression. Results: Sixty-five premature and 56 full-term infants were included. The percentage of immune individuals after vaccination against measles (100% vs. 100%) and varicella (92.5% vs. 93.2%) were similar in both groups, as well as the antibody levels against measles (2.393 vs. 2.412 UI/mL; p = 0.970) and varicella (0.551 vs. 0.399 UI/mL; p = 0.114). Use of antenatal corticosteroids decreased measles antibody levels whereas breastfeeding for more than six months increased varicella antibody levels. Conclusions: Humoral responses to measles and varicella were similar between infants born prematurely and full-term infants. Measles antibody levels were negatively associated with antenatal corticosteroid use; varicella antibodies were positively associated with prolonged breastfeeding.
Subject(s)
Humans , Male , Female , Infant , Infant, Premature/immunology , Infant, Very Low Birth Weight/immunology , Chickenpox Vaccine/immunology , Measles-Mumps-Rubella Vaccine/immunology , Immunity, Humoral/immunology , Breast Feeding , Enzyme-Linked Immunosorbent Assay , Linear Models , Chickenpox/immunology , Chickenpox/prevention & control , Prospective Studies , Gestational Age , Vaccination/methods , Statistics, Nonparametric , Measles/immunology , Measles/prevention & control , Antibodies, Viral/bloodABSTRACT
Infectious diseases have historically resulted in suspended or cancelled military operations. Vaccination for disease prevention is a critical component of the military's force readiness doctrine. Until recently, Korea had not recognized the importance of vaccinating military personnel. However, a 2011 meningococcal disease outbreak at an army recruit training center led to dramatic changes in the paradigm of traditional medical practice in the Korean armed forces. A new vaccination policy was formed by a 2012 Military Healthcare Service Act. Since then, Neisseria meningitidis, hepatitis A, and measles-mumps-rubella vaccines have been routinely administered to all new recruits early in basic training to ensure protection against these diseases. All active-duty soldiers also receive seasonal influenza vaccination annually. Despite quantitative improvements in vaccination policies, several instances of major infectious diseases and adverse vaccine reactions have threatened soldier health. In the future, vaccination policies in the Korean armed forces should be based on epidemiologic data and military medical research for vaccine use and safety management.
Subject(s)
Humans , Health Policy , Hepatitis A Vaccines/immunology , Influenza Vaccines/immunology , Measles-Mumps-Rubella Vaccine/immunology , Meningococcal Vaccines/immunology , Military Personnel , Republic of Korea , VaccinationABSTRACT
A non-controlled longitudinal study was conducted to evaluate the combined vaccine against measles, mumps and rubella (MMR) immunogenicity in 150 children vaccinated in the routine of three health units in the city of Rio de Janeiro, Brazil, 2008-2009, without other vaccines administered during the period from 30 days before to 30 days after vaccination. A previous study conducted in Brazil in 2007, in 1,769 children ranging from 12-15 months of age vaccinated against yellow fever and MMR simultaneously or at intervals of 30 days or more between doses, had shown low seroconversion for mumps regardless of the interval between administration of the two vaccines. The current study showed 89.5% (95% confidence interval: 83.3; 94.0) seroconversion rate for mumps. All children seroconverted for measles and rubella. After revaccination, high antibody titres and seroconversion rates were achieved against mumps. The results of this study and others suggest that two MMR doses confer optimal immunoresponses for all three antigens and the possible need for additional doses should be studied taking into account not only serological, but also epidemiological data, as there is no serological correlate of protection for mumps.
Subject(s)
Female , Humans , Infant , Male , Antibodies, Viral/immunology , Measles-Mumps-Rubella Vaccine/immunology , Mumps/immunology , Seroconversion , Antibodies, Viral/blood , Brazil , Immunization Schedule , Longitudinal Studies , Measles-Mumps-Rubella Vaccine/administration & dosage , Measles/immunology , Mumps/prevention & control , Rubella/immunologyABSTRACT
OBJETIVO : Estimar la seroprevalencia de rubéola y factores asociados. METODOS : Estudio de seroprevalencia poblacional con una muestra aleatoria de 2.124 individuos de seis a 64 años, representativa por edad, sexo y área en Medellín, Colombia, 2009. Se analizó la asociación de variables biológicas y socioeconómicas con la seroprotección para rubéola, según la cohorte del año de nacimiento antes (1954 a 1990) y después (1991 a 2003) del inicio de la vacunación universal. Se determinaron los títulos de IgG con pruebas de alta sensibilidad (AxSYM ® Rubella IgG – Laboratorio Abbott) y especificidad (VIDAS RUB IgG II ® – Laboratorio BioMerieux). Se estimaron proporciones y promedios ponderados derivados de un muestreo complejo incluyendo un factor de corrección por las diferencias en la participación por sexo. Se analizó la asociación de la protección por grupos de variables biológicas y sociales con un modelo de regresión logística, según la cohorte de nacimiento. RESULTADOS : Los títulos promedio de IgG fueron más altos en los nacidos antes del inicio de la vacunación (media 110 UI/ml; IC95% 100,5;120,2) que en los nacidos después (media 64 UI/ml; IC95% 54,4;72,8), p = 0,000. La proporción de protección fue creciente de 88,9% en los nacidos en 1990-1994, de 89,2% en 1995-1999 y de 92,1% en 2000 a 2003, posiblemente relacionado con la administración del refuerzo desde 1998. En los nacidos antes del inicio de la vacunación, la seroprotección estuvo asociada con el antecedente de contacto con casos (RD 2,6; IC95% 1,1;5,9), el estado de salud (RD 2,5; IC95% 1,05;6,0), el nivel de escolaridad (RD 0,2; IC95% 0,08;0,8) y los años de residencia del hogar en el barrio (RD 0,96; IC95% 0,98;1,0), luego de ajustar por todas las variables. En los nacidos después ...
OBJETIVO : Estimar a soroprevalência de rubéola e fatores associados. MÉTODOS : Estudo de soroprevalência em população a través de uma amostra aleatória de 2.124 indivíduos de seis a 64 anos, representativa por idade, sexo e área em Medellín, Colômbia, 2009. Foi analisada a associação de variáveis biológicas e socioeconômicas com a soroproteção para rubéola, de acordo com a coorte de nascimento antes (1954 a 1990) e depois (1991 a 2003) do inicio da vacinação universal. Foram determinados os títulos de IgG com testes de alta sensibilidade (AxSYM® Rubella IgG – Laboratório Abbott) e especificidade (VIDAS RUB IgG II® – Laboratório BioMerieux). Foram estimadas proporções e médias ponderadas derivadas de amostragem complexa incluindo um fator de correição pelas diferenças na participação por sexo. Foi analisada a associação da proteção por grupos de variáveis biológicas e sociais com um modelo de regressão logística, segundo a coorte de nascimento. RESULTADOS : As médias dos títulos de IgG foram maiores nos nascidos antes do inicio da vacinação (média 110UI/ml; IC95% 100,5;120,2) do que nos nascidos posteriormente (média 64 UI/ml; IC 95% 54,4;72,8), p = 0,000. A proporção de proteção foi crescente de 88,9% nos nascidos em 1990-1994, de 89,2% em 1995-1999 e de 92,1% em 2000 a 2003, provavelmente relacionado à administração do reforço desde 1998. A soroproteção esteve associada nos nascidos antes com o fato de ter contato com casos (RD 2,6; IC95% 1,1;5,9), o estado de saúde (RD 2,5; IC95% 1,05;6,0), o nível de escolaridade (RD 0,2; IC95% 0,08;0,8) e os anos morando no bairro (RD 0,96; IC95% 0,98;1,0), após ajuste por todas ...
OBJECTIVE : To estimate the seroprevalence of rubella and associated factors. METHODS : Population-based seroprevalence study in a random sample of 2,124 individuals, aged six to 64 years, representative by age, sex and area in Medellín, Colombia, 2009. Biological and socioeconomic variables were analyzed for their association with serum protection against rubella, according to birth-year cohort; those born before (1954-1990) and after (1991-2003) the introduction of universal immunization. Titer of IgG antibodies against the rubella virus was detected using a high sensitivity (AxSYM®Rubella IgG – Abbott Laboratories) and a high specificity test (VIDAS RUB IgG II®– BioMerieux Laboratories). Proportions and weighted averages derived from a complex sample, including a correction factor for differences in gender participation, were estimated. Association with protection for groups of biological and social variables according to birth cohort was analyzed using a logistic regression model. RESULTS : Titers of IgG antibodies were higher in those born before (mean 110 UI/ml, 95%CI 100.5;120.2) compared to those born after (mean 64 UI/ml; 95%CI 54.4;72.8; p = 0.000) the introduction of mass immunization. The proportion of protection increased from 88.9% in those born 1990-1994, to 89.2% in those born 1995-1999 and to 92.1% in those born between 2000 and 2003, possibly due to boosters being administered from 1998 onwards. In those born before the introduction of the immunization, seroprotection was associated with previous contact with cases (OR 2.6; 95%CI 1.1;5.9), self- perceived health status (OR 2.5; 95%CI 1.05;6.0), educational level (OR 0.2; 95%CI 0.08;0.8) and years of residence in the neighborhood (RD 0,96; 95%CI 0.98;1.0) after adjusting for all variables. In those born after, serum protection was associated with effective sleep time (OR 1,4; 95%CI 1.09;1.8) and self-perceived health status (OR 5.5; 95%CI ...
Subject(s)
Adolescent , Adult , Child , Female , Humans , Male , Middle Aged , Young Adult , Antibodies, Viral/blood , Immunoglobulin G/blood , Rubella virus/immunology , Rubella/epidemiology , Cohort Studies , Colombia/epidemiology , Mass Vaccination , Measles-Mumps-Rubella Vaccine/administration & dosage , Measles-Mumps-Rubella Vaccine/immunology , Risk Factors , Rubella/diagnosis , Seroepidemiologic StudiesABSTRACT
Background & objectives: MMR vaccine in a two dose schedule has successfully eliminated measles, mumps and rubella from many developed countries. In India, it is not a part of national immunization programme but is included in the State immunization programme of Delhi as a single dose between 15-18 months. This prospective study was carried out to assess the extent of seroprotection against these three diseases in immunized children and to study the immune response to a second dose of MMR. Methods: Consecutive children aged 4-6 yr, attending the immunization clinic of a tertiary care hospital in Delhi for routine DT vaccination, were enrolled. Second dose of MMR was given and pre- and post-vaccination antibody levels were compared. Results: The pre-vaccination percentage seropositivity observed in the 103 children recruited, was 20.4 per cent for measles, 87.4 per cent for mumps and 75.7 per cent for rubella. Amongst the 84 children who were followed up after the second dose, the percentage seroprotection for measles rose from 21.4 (18/84) to 72.6 per cent (61/84) and 100 per cent became seroprotected to mumps and rubella. Interpretation & conclusions: The percentage of children protected against measles was found to be alarmingly low which needs to be investigated. Though the observed protection against mumps and rubella was adequate, its durability was not known. The need for re-appraisal of the current MMR immunization policy is called for by carrying out longitudinal studies on a larger sample.
Subject(s)
Antibodies, Viral/blood , Child , Child, Preschool , Humans , India , Measles-Mumps-Rubella Vaccine/administration & dosage , Measles-Mumps-Rubella Vaccine/immunology , Prospective StudiesABSTRACT
OBJECTIVE: We evaluated the seroprevalence for measles, mumps, and rubella in school-age children (6-12 years old) before and after the administration of three triple combined viral vaccines. METHODS: In two municipal schools of Rio Grande do Sul, Brazil, 692 blood samples were collected before vaccination and 636 samples 21 to 30 days after vaccination during 1996. IgG antibody seropositivity was investigated by enzyme-linked immunosorbent assay (measles and mumps with Enzygnost [Behring, Marburg, Germany]; rubella with Rubenostika [Organon Teknica, Boxtel, the Netherlands]). The vaccines compared were: A: E-Zagreb, L-Zagreb, and Wistar RA 27/3 (Tresivac); B: Moraten, J-Lynn, and Wistar RA 27/3 (M-M-R II); and C: Schwarz, Urabe AM-9, and Wistar RA 27/3 (Trimovax). RESULTS: Before vaccination, 79.2 percent [95 percent confidence interval (CI) = 76.0 percent-82.2 percent] of the samples were positive for measles, 69.4 percent (95 percent CI = 65.8 percent-72.8 percent) for mumps, and 55.4 percent (95 percent CI = 51.6 percent-59.2 percent) for rubella. After vaccination with the A, B, and C vaccines, seropositivity was 100.0 percent, 99.5 percent, and 100.0 percent, respectively for measles; 99.5 percent, 94.5 percent, and 92.0 percent for mumps; and 92.6 percent, 91.3 percent, and 88.6 percent for rubella. CONCLUSIONS: About one-fifth (20.8 percent) of the schoolchildren who could have been vaccinated against measles at age 9 months had levels of antibodies insufficient for protection. In the sample of schoolchildren without previous vaccination against mumps and rubella, high proportions of susceptible levels were found. All vaccines were immunogenic, but vaccine A yielded a seroconversion rate of 99.5 percent for the mumps component, which was significantly higher than the other two vaccines (P < 0.01).
OBJETIVO: Se evaluó la seroprevalencia para sarampión, paperas y rubéola en niños en edad escolar (6-12 años) antes y después de la administración de tres vacunas triples antivirales combinadas. MÉTODOS: Se colectaron 692 muestras de sangre antes de la vacunación y 636 muestras entre 21 y 30 días después de la vacunación a niños de dos escuelas municipales de Rio Grande do Sul, Brasil, durante 1996. Se investigó la seropositividad de anticuerpos de la clase IgG mediante un ensayo de inmunoadsorción enzimática tipo ELISA (sarampión y paperas con Enzygnost [Behring, Marburgo, Alemania] y rubéola con Rubenostika [Organon Teknica, Boxtel, Países Bajos]). Las vacunas comparadas fueron: a) E-Zagreb, L-Zagreb y Wistar RA 27/3 (Tresivac); b) Moraten, J-Lynn y Wistar RA 27/3 (M-M-R II); y c) Schwarz, Urabe AM-9 y Wistar RA 27/3 (Trimovax). RESULTADOS: Antes de la vacunación, 79,2 por ciento (intervalo de confianza [IC] 95 por ciento: 76,0 a 82,2) de las muestras fueron positivas para sarampión, 69,4 por ciento (IC 95 por ciento: 65,8 a 72,8) para paperas y 55,4 por ciento (IC 95 por ciento: 51,6 a 59,2) para rubéola. Después de la vacunación con las vacunas A, B y C, la seropositividad fue de 100 por ciento, 99,5 por ciento y 100 por ciento, respectivamente para sarampión; de 99,5 por ciento, 94,5 por ciento y 92,0 por ciento para paperas; y de 92,6 por ciento, 92,3 por ciento y 88,6 por ciento para rubéola. CONCLUSIONES: Alrededor de un quinto (20,8 por ciento) de los escolares que pudieron haber sido vacunados contra el sarampión a los 9 meses de edad tenían niveles de anticuerpos insuficientes para protegerlos. En la muestra de escolares sin vacunación previa contra paperas y rubéola se encontró una alta proporción de niños susceptibles. Todas las vacunas fueron inmunogénicas, pero la vacuna A produjo una tasa de seroconversión de 99,5 por ciento para el componente de paperas, significativamente mayor que la de las otras dos vacunas (P < 0,01).
Subject(s)
Humans , Male , Female , Child , Antibodies, Viral/blood , Measles-Mumps-Rubella Vaccine/immunology , Brazil , Double-Blind Method , Measles/blood , Measles/epidemiology , Measles/prevention & control , Mumps/blood , Mumps/epidemiology , Mumps/prevention & control , Rubella/blood , Rubella/epidemiology , Rubella/prevention & control , Seroepidemiologic Studies , Time FactorsABSTRACT
Severe complications such as meningoencephalitis are quite rare in the setting of mumps infection. We report here on a 24-year-old soldier with a past history of MMR vaccination who was admitted because of aseptic meningitis. His mental status rapidly deteriorated and swelling of both parotid glands was observed. The MR findings revealed discrete lesions in the brainstem and thalamus. He barely recovered within 2 months. Among the adults with failure to acquire immunity despite MMR vaccination, institutional crowding can lead to cases of potentially fatal CNS complication such as mumps meningoencephalitis.